TOP TIERMARKET NEWSWIRE

News & sentiment

BRIDGEBIO PHARMA INC (BBIO) — News & AI sentiment

BRIDGEBIO PHARMA INC (BBIO) news roundup. 7 stories in the past week, 36 over 30 days. Average 30-day sentiment is 51.4/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 7 sales totalling $27.6M — net selling of $27.6M. US House Periodic Transaction Reports (90-day window): 1 purchase (~$8K) and 0 sales (~$0). Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

7

avg sentiment 57.9/100

30d stories

36

avg sentiment 51.4/100

Insider net (90d)

$27.6M

0 buys · 7 sells

Congress (90d)

1

1 buys · 0 sells

BBIO news in the last 24 hours, 7 days, 30 days and 90 days

How much BBIO coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	BBIO stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	7	57.9/100	BBIO headlines →
Last 30 days	36	51.4/100	BBIO headlines →
Last 90 days	83	53/100	BBIO headlines →

Latest stories on BBIO

JPMorgan cuts BridgeBio target, sees buying opportunity on selloff

The Fly54 · neutralanalyst

2d ago

BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

3d ago

BridgeBio Pharma: Attruby Peak Sales Set To Rise

Seeking Alpha63 · neutralanalyst

3d ago

H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy

Investing.com Analyst Ratings61 · neutralanalyst

3d ago

BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

4d ago

BridgeBio Pharma presents new exploratory analyses from PROPEL 3 at ESPE

The Fly59 · neutralproduct/pr

4d ago

Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC

GlobeNewswire56 · neutralgeneral

4d ago

Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President

Yahoo Top42 · neutralpotus

Sep 2

H.C. Wainwright reiterates Buy on BridgeBio stock on trial data

Investing.com Analyst Ratings61 · neutralanalyst

Sep 2

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

Business Insider56 · neutralproduct/pr

Sep 2

BridgeBio Pharma files $500M mixed securities shelf

The Fly28 · bearishgeneral

Sep 1

BridgeBio Pharma price target raised to $110 from $96 at Mizuho

The Fly63 · neutralanalyst

Sep 1

BridgeBio to Participate in September Investor Conferences

GlobeNewswire56 · neutralgeneral

Sep 1

BridgeBio to Participate in September Investor Conferences

StockTitan55 · neutralgeneral

Sep 1

BridgeBio Pharma Expands Access to Rare Disease Therapies

TipRanks63 · neutralproduct/pr

Aug 31

BridgeBio Pharma, Inc. (BBIO) files 8-K

SEC 8-K50 · neutralgeneral

Aug 31

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Business Insider63 · neutralproduct/pr

Aug 31

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

StockTitan56 · neutralgeneral

Aug 31

Mizuho raises BridgeBio Pharma stock price target to $110 on Attruby

Investing.com Analyst Ratings61 · neutralanalyst

Aug 31

BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study

The Fly63 · neutralproduct/pr

Aug 30

BridgeBio Pharma doses first patient in ASCEND-ATTR trial

The Fly56 · neutralproduct/pr

Aug 26

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

StockTitan58 · neutralproduct/pr

Aug 26

BridgeBio Pharma participates in a conference call with Cantor

The Fly55 · neutralgeneral

Aug 24

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

Business Insider63 · neutralproduct/pr

Aug 24

Exelixis, Valaris, and 3 More Stocks See Activist Action

Barron's50 · neutralgeneral

Aug 21

Open BBIO in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →